Theseus Pharmaceuticals Future Growth

Future criteria checks 0/6

Theseus Pharmaceuticals's earnings are forecast to decline at 6.3% per annum. EPS is expected to grow by 14.2% per annum.

Key information

-6.3%

Earnings growth rate

14.2%

EPS growth rate

Pharmaceuticals earnings growth	23.7%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	12 Feb 2024

Recent future growth updates

Recent updates

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Feb 01

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

Aug 18

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

May 05

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Dec 07

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Aug 11

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Apr 22

Earnings and Revenue Growth Forecasts

NasdaqGS:THRX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-66	N/A	-55	1
12/31/2025	N/A	-53	N/A	-42	1
12/31/2024	N/A	-49	N/A	-39	1
12/31/2023	N/A	-56	N/A	-48	1
9/30/2023	N/A	-57	-50	-50	N/A
6/30/2023	N/A	-58	-46	-46	N/A
3/31/2023	N/A	-55	-44	-44	N/A
12/31/2022	N/A	-51	-33	-33	N/A
9/30/2022	N/A	-46	-33	-33	N/A
6/30/2022	N/A	-38	-31	-31	N/A
3/31/2022	N/A	-33	-30	-30	N/A
12/31/2021	N/A	-27	-27	-27	N/A
9/30/2021	N/A	-22	-19	-19	N/A
6/30/2021	N/A	-16	-14	-14	N/A
3/31/2021	N/A	-13	-9	-9	N/A
12/31/2020	N/A	-12	-5	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: THRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: THRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: THRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if THRX's revenue is forecast to grow faster than the US market.

High Growth Revenue: THRX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if THRX's Return on Equity is forecast to be high in 3 years time

Theseus Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 70% to US$6.75

Recent updates

Theseus Pharmaceuticals Files Form 15

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from NASDAQ Composite Index

Concentra Biosciences, LLC completed the acquisition of Theseus Pharmaceuticals, Inc. (NasdaqGS:THRX).

Theseus Pharmaceuticals' Common Stock to be Cease Trading on Nasdaq at the Opening of Trading on February 14, 2024, and Intends Promptly to Cause to be Delisted from Nasdaq

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Theseus Pharmaceuticals, Inc. Announces Employment Termination of Timothy P. Clackson as Chief Executive Officer, Effective December 7, 2023

Theseus Pharmaceuticals, Inc. announced delayed 10-Q filing

Key Executive exercised options to buy US$555k worth of stock.

New minor risk - Market cap size

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

New major risk - Share price stability

Price target decreased by 70% to US$6.75

Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of The-630 in Patients with Gist

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Less than half of directors are independent

Theseus Pharmaceuticals Presents Preclinical Data Characterizing The-349, Its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium

Theseus Pharmaceuticals, Inc. Appoints Steven Stein to Board of Directors

Theseus Pharmaceuticals, Inc. Nominates The-349, A Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Theseus Pharmaceuticals, Inc.(NasdaqGS:THRX) dropped from Russell 2000 Growth Index

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

Less than half of directors are independent

Theseus Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

Theseus Pharmaceuticals, Inc. Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (Egfr) Inhibitors At the 2022 American Association for Cancer Research (Aacr) Annual Meeting

Theseus Pharmaceuticals Announces First Patient Treated with The-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies